Colchicine in stroke prevention: potential benefits and limitations of an anti-inflammatory therapy.

Front Neurol · 2025 · PMC11864930 · PMID 40017533

Europe PMC DOI

hedged sentences

0.0900

closest p · 1.8× alpha

0.0900

boldest claim

The sentences

did not reach statistical significancep = 0.09so close (0.05 < p ≤ 0.1)

In a subgroup analysis by age, patients under 65 showed a significant reduction in stroke rate (RR: 0.35; 95% CI: 0.16–0.74; p < 0.01), while the reduction in patients over 65 did not reach statistical significance (RR: 0.60; 95% CI: 0.33–1.09, p = 0.09) ( 10 ).

also in 111,027 other papers

showed a trendno p-value reported

Pravastatin (OR 13.67) and lovastatin (OR 8.60) showed a trend toward lower myopathy risk when combined with colchicine, whereas atorvastatin (OR 25.73), rosuvastatin (OR 25.73), and simvastatin (OR 30.08) demonstrated similar risks when used with colchicine.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.